MCE 的所有產(chǎn)品僅用作科學研究或藥證申報,，我們不為任何個人用途提供產(chǎn)品和服務。

Capivasertib

CAS No. : 1143532-39-1

MCE 國際站：Capivasertib

產(chǎn)品活性：Capivasertib (AZD5363) 是一種口服有效的 pan-AKT 激酶抑制劑,，抑制 Akt1,，Akt2 和 Akt3，IC₅₀ 分別為 3,，7 和 7 nM,。

研究領域：PI3K/Akt/mTOR  |  Autophagy

作用靶點：Akt  |  Autophagy

In Vitro: Capivasertib, a novel pyrrolopyrimidine-derived compound, inhibits all AKT isoforms with a potency of 10 nM or less. Capivasertib inhibits phosphorylation of these substrates with an IC₅₀ value of 0.06 to 0.76 μM in the 3 cell lines. Capivasertib effectively inhibits phosphorylation of S6 and 4E-BP1 in these cell lines, whereas it increases phosphorylation of AKT at both ser⁴⁷³ and thr³⁰⁸. In BT474c cells, Capivasertib induces FOXO3a nuclear translocation with EC₅₀ value of 0.69 μM; a concentration of 3 μM is sufficient to almost completely localize FOXO3a to the nucleus. AZD5363Capivasertibhibitor MK-2206 is much less active (IC₅₀>30 μM).

In Vivo: Oral dosing of Capivasertib (AZD5363) to nude mice causes dose- and time-dependent reduction of PRAS40, GSK3β, and S6 phosphorylation in BT474c xenografts (PRAS40 phosphorylation EC₅₀ ~0.1 μM total plasma exposure), reversible increases in blood glucose concentrations, and dose-dependent decreases in 2[¹⁸F]fluoro-2-deoxy-D-glucose (¹⁸F-FDG) uptake in U87-MG xenografts. Chronic oral dosing of Capivasertib caused dose-dependent growth inhibition of xenografts derived from various tumor types, including HER2⁺ breast cancer models. Capivasertib also significantly enhances the antitumor activity of RP-56976 and GW572016 in breast cancer xenografts.

相關產(chǎn)品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  PI3K/Akt/mTOR Compound Library  |  Stem Cell Signaling Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Anti-diabetic Compound Library  |  Oxygen Sensing Compound Library  |  Anti-COVID-19 Compound Library  |  Glycolysis Compound Library  |  Cytoskeleton Compound Library  |  Orally Active Compound Library  |  Glutamine Metabolism Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Anti-Obesity Compound Library  |  Angiogenesis-Related Compound Library  |  Glucose Metabolism Compound Library  |  Targeted Diversity Library  |  Anti-Liver Cancer Compound Library   |  Anti-Colorectal Cancer Compound Library   |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Cancer Stem Cells Compound Library  |  Heterocyclic Compound Library  |  Pain-Related Compound Library  |  Membrane Protein-targeted Compound Library  |  Cell Death Library  |  Serine/Threonine Kinase Inhibitor Library  |  Anti-Hematopathy Compound Library  |  Anti-Ovarian Cancer Compound Library  |  Multi-Target Compound Library  |  Bioactive Compound Library Max  |  Anti-Gastric Cancer Compound Library  |  Anti-Fibrosis Compound Library  |  Anti-Brain Cancer Compound Library  |  Protein Kinase Compound Library  |  Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library  |  Cell Proliferation Compound Library  |  Deferoxamine mesylate  |  MK-2206 dihydrochloride  |  Yoda 1  |  SC79  |  Afatinib  |  Ipatasertib  |  Chloramphenicol  |  Honokiol  |  α-Linolenic acid  |  Ergothioneine  |  Oridonin  |  AKT inhibitor VIII  |  Artemisinin  |  Isoginkgetin  |  Scutellarin  |  Recilisib  |  GSK-690693  |  ZINC00640089  |  Patritumab  |  Guggulsterone  |  UCL-TRO-1938  |  Miransertib  |  Bisphenol A  |  Berberine sulfate  |  PI3K/Akt/CREB activator 1  |  Heclin  |  L-Valine  |  PRE-084 hydrochloride

熱門產(chǎn)品線：重組蛋白  |  藥物篩選  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標記物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介紹:
?   MCE (MedChemExpress) 擁有200 多種全球獨家化合物庫，我們致力于為全球科研客戶提供前沿最全的高品質(zhì)小分子活性化合物,；
?   50,000 多種高選擇性抑制劑,、激動劑涉及各熱門信號通路及疾病領域；
?   產(chǎn)品種類涵蓋各種重組蛋白,，多肽,，常用試劑盒 ，更有 PROTAC,、ADC 等特色產(chǎn)品,，廣泛應用于新藥研發(fā)、生命科學等科研項目；
?   提供虛擬篩選,，離子通道篩選,，代謝組學分析檢測分析，藥物篩選等專業(yè)技術服務,；
?   設有專業(yè)的實驗中心和嚴格的質(zhì)控,、驗證體系；
?   提供 LC/MS,、NMR,、HPLC、手性分析,、元素分析等各項質(zhì)檢報告,，確保產(chǎn)品的高純度、高品質(zhì),；
?   產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證,；
?   Nature, Cell, Science 等多種頂級期刊及制藥專利收錄了MCE客戶的科研成果；
?   專業(yè)團隊跟蹤最新的制藥及生命科學研究進展,，為您提供全球最新的活性化合物,；
?   與世界各大制藥公司及知名科研機構建立了長期的合作。